Limits...
Antibodies to early EBV, CMV, and HHV6 antigens in systemic lupus erythematosus patients.

Rasmussen NS, Draborg AH, Nielsen CT, Jacobsen S, Houen G - Scand. J. Rheumatol. (2015)

Bottom Line: Furthermore, EBV EA/D- and CMV pp52-directed IgG levels were inversely and positively associated, respectively, with lymphocyte counts in SLE patients.None of the findings seemed to be associated with use of immunosuppressive medication.Our results suggest strong, but opposite, associations of lytic EBV and CMV infections with SLE.

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut , Copenhagen , Denmark.

ABSTRACT

Objectives: We investigated the antibody levels against early antigens of Epstein-Barr virus (EBV), cytomegalovirus (CMV), and human herpesvirus 6 (HHV6) in systemic lupus erythematosus (SLE) patients and healthy controls, and further correlated these antibodies to haematology/biochemistry, serology, and disease activity measures.

Method: Immunoglobulin (Ig)M, IgG, and IgA levels against the DNA polymerase processivity factors of EBV, CMV, and HHV6, termed early antigen diffuse (EA/D), pp52, and p41, respectively, were determined in plasma samples from 77 SLE patients and 29 healthy controls by using enzyme-linked immunosorbent assays (ELISAs).

Results: IgM, IgG, and IgA levels against EBV EA/D, and IgG and IgA levels against CMV pp52, were significantly higher in SLE patients compared with healthy controls. Furthermore, EBV EA/D- and CMV pp52-directed IgG levels were inversely and positively associated, respectively, with lymphocyte counts in SLE patients. None of the findings seemed to be associated with use of immunosuppressive medication.

Conclusions: Our results suggest strong, but opposite, associations of lytic EBV and CMV infections with SLE. The amplified humoral responses to EBV EA/D and CMV pp52 in our SLE patient cohort probably reflect aberrant control of EBV and CMV reactivation. However, reactivation of EBV appeared to correlate with lymphopenic manifestations in SLE patients whereas CMV reactivation seemed to correlate with increments in lymphocyte levels.

Show MeSH

Related in: MedlinePlus

Two-group comparisons of (A) EBV EA/D-, (B) CMV pp52-, and (C) HHV6 p41-directed (i) IgM, (ii) IgG, and (iii) IgA levels between SLE patients (n = 77) and healthy controls (n = 29). The antibody levels are presented in arbitrary units (AU). The horizontal bars represent medians and interquartile ranges. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4389709&req=5

Figure 1: Two-group comparisons of (A) EBV EA/D-, (B) CMV pp52-, and (C) HHV6 p41-directed (i) IgM, (ii) IgG, and (iii) IgA levels between SLE patients (n = 77) and healthy controls (n = 29). The antibody levels are presented in arbitrary units (AU). The horizontal bars represent medians and interquartile ranges. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.

Mentions: The SLE patients had significantly higher IgM, IgG, and IgA levels against EBV EA/D compared with healthy controls (p = 0.02, < 0.001, and < 0.001, respectively; Figure 1Ai–iii) (Cliff's δ = 0.29, 0.72, and 0.49, respectively; Supplementary Table S1), and significantly higher IgG and IgA levels against CMV pp52 compared with healthy controls (p = 0.009 and 0.004, respectively; Figure 1Bii, iii) (Cliff's δ = 0.33 and 0.37, respectively). By contrast, no significant differences were detected in IgM, IgG, and IgA levels against HHV6 p41 (Figure 1Ci–iii) or in IgM levels against CMV pp52 between the two groups (Figure 1Bi).


Antibodies to early EBV, CMV, and HHV6 antigens in systemic lupus erythematosus patients.

Rasmussen NS, Draborg AH, Nielsen CT, Jacobsen S, Houen G - Scand. J. Rheumatol. (2015)

Two-group comparisons of (A) EBV EA/D-, (B) CMV pp52-, and (C) HHV6 p41-directed (i) IgM, (ii) IgG, and (iii) IgA levels between SLE patients (n = 77) and healthy controls (n = 29). The antibody levels are presented in arbitrary units (AU). The horizontal bars represent medians and interquartile ranges. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4389709&req=5

Figure 1: Two-group comparisons of (A) EBV EA/D-, (B) CMV pp52-, and (C) HHV6 p41-directed (i) IgM, (ii) IgG, and (iii) IgA levels between SLE patients (n = 77) and healthy controls (n = 29). The antibody levels are presented in arbitrary units (AU). The horizontal bars represent medians and interquartile ranges. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.
Mentions: The SLE patients had significantly higher IgM, IgG, and IgA levels against EBV EA/D compared with healthy controls (p = 0.02, < 0.001, and < 0.001, respectively; Figure 1Ai–iii) (Cliff's δ = 0.29, 0.72, and 0.49, respectively; Supplementary Table S1), and significantly higher IgG and IgA levels against CMV pp52 compared with healthy controls (p = 0.009 and 0.004, respectively; Figure 1Bii, iii) (Cliff's δ = 0.33 and 0.37, respectively). By contrast, no significant differences were detected in IgM, IgG, and IgA levels against HHV6 p41 (Figure 1Ci–iii) or in IgM levels against CMV pp52 between the two groups (Figure 1Bi).

Bottom Line: Furthermore, EBV EA/D- and CMV pp52-directed IgG levels were inversely and positively associated, respectively, with lymphocyte counts in SLE patients.None of the findings seemed to be associated with use of immunosuppressive medication.Our results suggest strong, but opposite, associations of lytic EBV and CMV infections with SLE.

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut , Copenhagen , Denmark.

ABSTRACT

Objectives: We investigated the antibody levels against early antigens of Epstein-Barr virus (EBV), cytomegalovirus (CMV), and human herpesvirus 6 (HHV6) in systemic lupus erythematosus (SLE) patients and healthy controls, and further correlated these antibodies to haematology/biochemistry, serology, and disease activity measures.

Method: Immunoglobulin (Ig)M, IgG, and IgA levels against the DNA polymerase processivity factors of EBV, CMV, and HHV6, termed early antigen diffuse (EA/D), pp52, and p41, respectively, were determined in plasma samples from 77 SLE patients and 29 healthy controls by using enzyme-linked immunosorbent assays (ELISAs).

Results: IgM, IgG, and IgA levels against EBV EA/D, and IgG and IgA levels against CMV pp52, were significantly higher in SLE patients compared with healthy controls. Furthermore, EBV EA/D- and CMV pp52-directed IgG levels were inversely and positively associated, respectively, with lymphocyte counts in SLE patients. None of the findings seemed to be associated with use of immunosuppressive medication.

Conclusions: Our results suggest strong, but opposite, associations of lytic EBV and CMV infections with SLE. The amplified humoral responses to EBV EA/D and CMV pp52 in our SLE patient cohort probably reflect aberrant control of EBV and CMV reactivation. However, reactivation of EBV appeared to correlate with lymphopenic manifestations in SLE patients whereas CMV reactivation seemed to correlate with increments in lymphocyte levels.

Show MeSH
Related in: MedlinePlus